Posted on 12/16/2020 12:15:01 PM PST by grundle
Time and time and time again, the official medical community kept telling us, over and over and over, that Trump was wrong about Hydroxychloroquine.
However, now that the election is over, they are finally admitting that Trump was right.
This website tracks the number of people who died because of their delay:
The estimated number of human lives lost from incorrect HCQ advice is:
803,673
based on a meta-analysis of all 24 early treatment studies and excluding areas already using HCQ. 100% of early treatment studies report a positive effect, with a 65% improvement in a random-effects meta-analysis, relative risk 0.35 [0.27-0.46].
I don’t know what it will take to dispel this inaccurate story.
First, the proposed change was from a delegation for consideration by the AMA congress, not a statement from AMA.
Second, it didn’t claim AMA had erred regarding efficacy of HCQ, only that the AMA should not stand in the way of patient-doctor right to off-label use.
Third, the AMA rejected the resolution and will continue to pressure doctors not to prescribe HCQ for Covid.
Regardless, I am convinced that AMA is acting politically, not basing their position on history or on the worldwide clinical experience with HCQ regimens.
Accordingly, I have the components of the HCQ-Ax-Zn regimen ready to use at the first sign of infection.
It turns out the AMA’s committee Resolution A in the below information re HCQ/Zinc WAS NOT ADOPTED! AMA position is UNCHANGED.
Scroll down to Resolution A:
Earlier, I sent you information that the AMA had recommended physicians be permitted to prescribe off label combinations of drugs for CV 19 that are in common use. It was a committee recommendation. It was not approved. AMA is back to their original recommendation of “no”. The text that follows depicts the discussion.
Just when you think the AMA is acting rationally...and then....it’s the same old AMA.
RESOLUTION 509 – HYDROXYCHLOROQUINE AND
7 COMBINATION THERAPIES – OFF-LABEL USE
8
9 RECOMMENDATION A:
10
11 Resolution 509 not be adopted.
12
13 RECOMMENDATION B:
14
15 Policy H-120.988 be reaffirmed.
16
17 HOD ACTION: Policy H-120.988 reaffirmed.
18
19
20 RESOLVED, that our American Medical Association rescind its statement calling for
21 physicians to stop prescribing hydroxychloroquine and chloroquine until sufficient evidence
22 becomes available to conclusively illustrate that the harm associated with use outweighs
23 benefit early in the disease course. Implying that such treatment is inappropriate contradicts
24 AMA Policy H-120.988 that addresses off label prescriptions as appropriate in the judgement
25 of the prescribing physician; (New HOD Policy) and be it further
26
27 RESOLVED, that our AMA rescind its joint statement with the American Pharmacists
28 Association and American Society of Health System Pharmacists, and update it with a joint
29 statement notifying patients that further studies are ongoing to clarify any potential benefit of
30 hydroxychloroquine and combination therapies for the treatment of COVID-19; (New HOD
31 Policy) and be it further
32
33 RESOLVED, that our AMA reassure the patients whose physicians are prescribing
34 hydroxychloroquine and combination therapies for their early-stage COVID-19 diagnosis by
35 issuing an updated statement clarifying our support for a physician’s ability to prescribe an
36 FDA-approved medication for off label use, if it is in her/his best clinical judgement, with
37 specific reference to the use of hydroxychloroquine and combination therapies for the
38 treatment of the earliest stage of COVID-19; (New HOD Policy) and be it further
39
40 RESOLVED, that our AMA take the actions necessary to require local pharmacies to fill valid
41 prescriptions that are issued by physicians and consistent with AMA principles articulated n
42 AMA Policy H-120.988, including working with the American Pharmacists Association and
43 American Society of Health System Pharmacists. (New HOD Policy)
44
45 Your Reference Committee reviewed passionate and mixed testimony from both the online
46 testimony and in the live hearing on this resolution.
47
48 Your AMA Board of Trustees (BOT) provided testimony in opposition of this Resolution and
49 supportive of the AMA statement. The BOT noted that several commentors misconstrued the
50 language in the statement and outlined that it very clearly says, “Novel off-label use of FDA
Reference Committee E (November 2020 Meeting)
Page 16 of 18
1 approved medications is a matter for the physician’s or other prescriber’s professional
2 judgment” and also emphasized the need for physicians to rely on their professional judgment
3 and medical evidence for any potential COVID-19 treatment option. The statement further
4 notes that any use of these medications should be coordinated with a treating physician with
5 full understanding of the potential risks and benefits. The statement was accurate at the time
6 it was issued and took the best evidence available into account. The BOT, CSAPH, and the
7 majority of those who testified noted that while hydroxychloroquine has demonstrated benefits
8 for multiple chronic autoimmune and rheumatologic diseases, the benefit for treatment of
9 COVID-19, at the time of the statement, had not been established, and that the AMA should
10 base statements and policy on evidence and science. Many commentors, including the BOT
11 and CSAPH noted that since the release of the statement several well-designed studies have
12 failed to find benefit in the use of hydroxychloroquine for treatment of COVID-19 in multiple
13 settings. Several who testified also noted that it would be an embarrassment to the AMA and
14 call the credibility of the AMA into question to rescind a statement that was evidence-based
15 and accurate.
16
17 Those supportive of Resolution 509 noted that the statement was offensive to physicians and
18 could undermine the patient-physician relationship. Your Reference Committee understands,
19 and agrees with the need for physician autonomy, but also agrees with the BOT testimony
20 that the AMA statement does not infringe on physician autonomy and thus should not be
21 rescinded. Your Reference Committee feels that AMA Policy H-120.988, “Patient Access to
22 Treatments Prescribed by Their Physicians,” very clearly articulates the AMA’s strong support
23 for autonomous clinical decision-making authority of physicians. Therefore, your Reference
24 Committee recommends that Resolution 509 not be adopted and Policy H-120.988 be
25 reaffirmed.
26
27 H-120.988, “Patient Access to Treatments Prescribed by Their Physicians”
28 1. Our AMA confirms its strong support for the autonomous clinical decision-making
29 authority of a physician and that a physician may lawfully use an FDA approved
30 drug product or medical device for an off-label indication when such use is based
31 upon sound scientific evidence or sound medical opinion; and affirms the position
32 that, when the prescription of a drug or use of a device represents safe and
33 effective therapy, third party payers, including Medicare, should consider the
34 intervention as clinically appropriate medical care, irrespective of labeling, should
35 fulfill their obligation to their beneficiaries by covering such therapy, and be
36 required to cover appropriate ‘off-label’ uses of drugs on their formulary.
37 2. Our AMA strongly supports the important need for physicians to have access to
38 accurate and unbiased information about off-label uses of drugs and devices, while
39 ensuring that manufacturer-sponsored promotions remain under FDA regulation.
40 3. Our AMA supports the dissemination of generally available information about off-
41 label uses by manufacturers to physicians. Such information should be
42 independently derived, peer reviewed, scientifically sound, and truthful and not
43 misleading. The information should be provided in its entirety, not be edited, or
44 altered by the manufacturer, and be clearly distinguished and not appended to
45 manufacturer-sponsored materials. Such information may comprise journal
46 articles, books, book chapters, or clinical practice guidelines. Books or book
47 chapters should not focus on any particular drug. Dissemination of information by
48 manufacturers to physicians about off-label uses should be accompanied by the
49 approved product labeling and disclosures regarding the lack of FDA approval for
50 such uses, and disclosure of the source of any financial support or author financial
51 conflicts.
Reference Committee E (November 2020 Meeting)
Page 17 of 18
1 4. Physicians have the responsibility to interpret and put into context information
2 received from any source, including pharmaceutical manufacturers, before making
3 clinical decisions (e.g., prescribing a drug for an off-label use).
4 5. Our AMA strongly supports the addition to FDA-approved labeling those uses of
5 drugs for which safety and efficacy have been demonstrated.
6 6. Our AMA supports the continued authorization, implementation, and coordination
7 of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity
8 Act.
Undoubtedly
.
Last possible moment hasn’t happened for her as it has for AMA
Neil Who? If no one watches or hears, did anyone say or hear anything?
Fake news. Just a resolution. Defeated.
All deserve execution. They purposefully murdered mass numbers of people for political gain.
Wait a minute. Didn’t the governor of Illinois go to jail for a number of years for talking about “selling” Barack Obama’s seat when he became President? I don’t think he did it. I think he just talked about doing it. Kamala should not have anything to do with her replaces her. I guess they will just invoke one of the Democrat’s favorite rules … “But that’s different”.
Election isn’t even close to being over...F-—Nut!
Leaving Mexico right now, with 40 HCQ tabs that I got OTC.
Screw the AMA and everyone else who killed tens of thousands for political or monetary reasons. I will do what is best for me and mine, period.
Now that is page 19 worthy news.
There’s a warm place reserved for these people.
“Kamala should not have anything to do with her replaces her. “
I can’t imagine a world where a Democrat who has something valuable would give it up without some quid pro quo. If she’s smart she won’t write down anything in texts or emails. At most, she will use a go-between. All other negotiations will be in person. That seat is worth a minimum of the cost of running a campaign; $10,000,000. She will get something...most likely an intangible and thoroughly deniable quid pro quo.
As for Blagovich, as I recall he tried for cash. (Pretty damn stupid in today’s world. The way it’s done is by paying a publisher to give someone a book contract. Look up Hillary on Amazon to see how it works.)
The AMA has voted to continue to stand in the way of patient-doctor right to off-label use.Cui bono?The AMA will continue to pressure doctors not to prescribe HCQ for Covid.
Typo?
Looks like the AMA waited until the LAST day of October to post this resolution! Four days before the election.
What does HCQ cost down there? Are there quantity limitations? Are they selling 200 mg? Sulfate or hcl? Thanks.
Bump
This is disgusting beyond all belief. How many lives could have been saved, for pennies, if the AMA hadn’t buckled last March to the pressure of the Trump hating Fake News?
How many lives more lives would have been saved if Andrew Cuomo, and other Democrat governors, had been called out for ordering active Covid-19 carriers into nursing homes?
Would the pandemic have happened at all if our China policy wasn’t warped by the crudest corruption, e.g. Red China bribing Hunter Biden to pay for his addictions to cocaine, hooker and child pornography?
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.